Medicare Enrolled
Dr. Jayasree Rao, M.D.
Medical Oncology · San Antonio, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Rao from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rao? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rao
Dr. Jayasree Rao is a medical oncology in San Antonio, TX, with 19 years in practice. Based on federal Medicare data, Dr. Rao performed 204,265 Medicare services across 2,410 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rao received a total of $15,672 from 88 pharmaceutical and/or device companies across 864 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rao is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 3% volume in TX$ $15,672 industry payments
Medicare Practice Summary
Medicare Utilization ↗204,265
Medicare services
Top 3% in TX for medical oncology
2,410
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~10,751 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | 69,120 | $0 | $3 |
| Filgrastim injection (Nivestym) for white blood cells | 33,120 | $0 | $1 |
| Iron sucrose injection (Venofer) | 28,800 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) | 15,900 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 12,360 | $18 | $47 |
| Epoetin alfa injection (Retacrit) for anemia | 8,340 | $6 | $16 |
| Dexamethasone injection (steroid) | 7,793 | $0 | $1 |
| Anti-nausea injection (ondansetron/Zofran) | 6,455 | $0 | $2 |
| Epoetin alfa injection (Procrit) for anemia | 3,220 | $6 | $15 |
| Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg | 2,390 | $52 | $193 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 2,301 | $22 | $56 |
| Iron infusion (Monoferric) | 2,200 | $17 | $43 |
| Office visit, established patient (30-39 min) | 2,187 | $93 | $249 |
| Immune globulin infusion (Gammagard) | 1,220 | $36 | $91 |
| Drug injection, under skin or into muscle | 990 | $11 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 851 | $48 | $123 |
| Unclassified drugs | 648 | $1 | $2 |
| Injection, diphenhydramine hcl, up to 50 mg | 613 | $1 | $2 |
| Administration of chemotherapy into vein, 1 hour or less | 580 | $100 | $252 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 458 | $16 | $40 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 424 | $15 | $38 |
| Injection, calcium gluconate (fresenius kabi), per 10 mg | 377 | $0 | $1 |
| Ceftriaxone antibiotic injection | 368 | $0 | $1 |
| Injection, iron dextran, 50 mg | 358 | $13 | $34 |
| Office visit, established patient, complex (40-54 min) | 316 | $131 | $349 |
| Office visit, established patient (20-29 min) | 280 | $69 | $176 |
| Injection, potassium chloride, per 2 meq | 280 | $0 | $1 |
| Injection of additional new drug or substance into vein | 241 | $12 | $30 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 240 | $1 | $3 |
| Administration of additional new drug or substance into vein, 1 hour or less | 214 | $50 | $124 |
| Injection, ketorolac tromethamine, per 15 mg | 214 | $0 | $2 |
| Administration of chemotherapy into vein, each additional hour | 212 | $22 | $54 |
| Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg | 209 | $449 | $1,789 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 183 | $1 | $4 |
| Infusion into a vein for hydration, 31-60 minutes | 182 | $24 | $63 |
| Prothrombin time test (blood clotting) | 131 | $4 | $9 |
| New patient office visit, complex (60-74 min) | 110 | $162 | $428 |
| Infusion into a vein for hydration, each additional hour | 84 | $10 | $25 |
| Irrigation of implanted venous access drug delivery device | 82 | $17 | $49 |
| Drawing of blood for a medical problem | 82 | $66 | $187 |
| Injection, vancomycin hcl, 500 mg | 36 | $2 | $6 |
| Injection of drug or substance into vein | 28 | $29 | $72 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 27 | $4 | $11 |
| Blood draw (venipuncture) | 23 | $8 | $17 |
| Injection, calcium gluconate (fresenius kabi), per 10 ml | 18 | $4 | $10 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.9% high complexity
94.1% medium
2.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$15,672
Total received (2018-2024)
Avg $2,239/year across 7 years
Top 33% in TX for medical oncology
88
Companies
864
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,939 (95.3%)
Other
Charitable contributions, space rental, and other categories
$682 (4.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$52 (0.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$908
2023$3,772
2022$2,668
2021$2,364
2020$555
2019$2,520
2018$2,886
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,982
Janssen Biotech, Inc.
$1,189
E.R. Squibb & Sons, L.L.C.
$1,062
Genentech USA, Inc.
$691
AstraZeneca Pharmaceuticals LP
$581
Celgene Corporation
$580
GENZYME CORPORATION
$563
Amgen Inc.
$501
Eisai Inc.
$418
PFIZER INC.
$404
Merck Sharp & Dohme Corporation
$368
Boehringer Ingelheim Pharmaceuticals, Inc.
$345
Teva Pharmaceuticals USA, Inc.
$322
Puma Biotechnology, Inc.
$288
Daiichi Sankyo Inc.
$255
Bayer HealthCare Pharmaceuticals Inc.
$230
Takeda Pharmaceuticals U.S.A., Inc.
$224
Incyte Corporation
$223
Astellas Pharma US Inc
$190
Karyopharm Therapeutics Inc.
$186
Rigel Pharmaceuticals, Inc.
$182
Lilly USA, LLC
$176
Seagen Inc.
$171
Gilead Sciences, Inc.
$167
Ipsen Biopharmaceuticals, Inc
$165
EISAI INC.
$154
GlaxoSmithKline, LLC.
$147
Pharmacyclics LLC, An AbbVie Company
$138
Myriad Genetic Laboratories, Inc.
$137
Organon LLC
$136
Kite Pharma, Inc.
$130
PUMA BIOTECHNOLOGY, INC.
$127
Novo Nordisk Inc
$125
Taiho Oncology, Inc.
$119
Kyowa Kirin, Inc.
$119
ARRAY BIOPHARMA INC
$118
Helsinn Therapeutics (U.S.), Inc.
$117
JAZZ PHARMACEUTICALS INC.
$105
Amneal Pharmaceuticals LLC
$103
Merck Sharp & Dohme LLC
$100
TerSera Therapeutics LLC
$94
ABBVIE INC.
$92
Regeneron Healthcare Solutions, Inc.
$90
EMD Serono, Inc.
$89
AMAG Pharmaceuticals, Inc.
$85
Bayer Healthcare Pharmaceuticals Inc.
$83
SOBI, INC
$82
Seattle Genetics, Inc.
$81
ADC Therapeutics America, Inc.
$77
Foundation Medicine, Inc.
$74
Octapharma USA, Inc.
$73
AVEO Pharmaceuticals, Inc.
$72
Pharmacosmos Therapeutics Inc.
$72
Alexion Pharmaceuticals, Inc.
$69
MorphoSys, US Inc.
$69
BeiGene USA, Inc.
$68
Exelixis Inc.
$68
Dova Pharmaceuticals
$68
PharmaEssentia USA Corporation
$66
Sobi, Inc
$60
Sandoz Inc.
$54
CTI BioPharma Corp.
$52
AbbVie, Inc.
$46
Janssen Pharmaceuticals, Inc
$45
Deciphera Pharmaceuticals Inc.
$42
Mylan Institutional Inc.
$39
Adaptive Biotechnologies Corporation
$39
Spectrum Pharmaceuticals Inc.
$38
Verastem, Inc.
$38
SERVIER PHARMACEUTICALS LLC
$35
Aveo Pharmaceuticals, Inc.
$34
Clovis Oncology, Inc.
$33
R-Pharm US LLC
$25
Sumitomo Pharma America, Inc.
$25
Sun Pharmaceutical Industries Inc.
$24
Apellis Pharmaceuticals, Inc.
$23
NOVARTIS PHARMACEUTICALS CORPORATION
$23
TESARO, Inc.
$22
Tempus AI, Inc
$22
Agios Pharmaceuticals, Inc.
$20
Blueprint Medicines Corporation
$18
TAIHO ONCOLOGY, INC.
$17
Mirati Therapeutics, Inc.
$17
Tactile Systems Technology Inc
$14
Coherus Biosciences Inc.
$14
INSYS Therapeutics Inc
$14
Epizyme, Inc.,
$13
Lexicon Pharmaceuticals, Inc.
$13
Top 3 companies account for 27.0% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AKYNZEO · ALIMTA · ALOXI · AVASTIN · AYVAKIT · Alecensa · Aliqopa · Aranesp · Avastin · BALVERSA · BAVENCIO · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELITEK · EMEND · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · EVENITY · Empaveli · Enhertu · Erleada · FARESTON · FERAHEME · FOTIVDA · FOUNDATIONONE · Flexitouch Plus · Folotyn · Fulphila · GAZYVA · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Ixempra · JADENU · JAKAFI · JARDIANCE · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · Monoferric · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · ORGOVYX · Ogivri · Onivyde · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PRADAXA · PRECISETUMOR · PROMACTA · PYRUKYND · Padcev · Perjeta · Phesgo · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · RYDAPT · Revlimid · Rezlidhia · Rubraca · SANCUSO · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SPRYCEL · SYNDROS · Somatuline Depot · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · Truxima · ULTOMIRIS · Udenyca · VENCLEXTA · VOTRIENT · VYXEOS · Vectibix · Venclexta · Vonjo · Wegovy · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · YONSA · Yescarta · ZARXIO · ZEJULA · ZEPZELCA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (95%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $8 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
37
Per 100K population
1.8
County median income
$70,571
Nearest hospital
BAPTIST MEDICAL CENTER
1.2 mi
1.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Rao is a mixed practice specialist, with above-average Medicare volume (top 3% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Rao experienced with injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram?
Based on Medicare claims data, Dr. Rao performed 69,120 injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rao receive payments from pharmaceutical companies?
Yes. Dr. Rao received a total of $15,672 from 88 companies across 864 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rao's costs compare to other medical oncologys in San Antonio?
Dr. Rao's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rao) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in San Antonio
Browse medical oncologys in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology